ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY · AIDP · AMAN · AMSAN
A physician-led, laboratory-verified treatment programme targeting residual neurological deficits after Guillain-Barré Syndrome — designed to accelerate peripheral nerve remyelination, restore motor function and reduce long-term disability through personalised biological intervention.
Request Medical ConsultationAbout the Condition
Guillain-Barré Syndrome (GBS) is an acute autoimmune disorder of the peripheral nervous system. The immune system — typically triggered by a preceding infection — attacks the myelin sheath and, in some variants, the axons of peripheral nerves. This results in rapidly progressive weakness, sensory disturbance and, in severe cases, respiratory failure requiring ventilation.
Most patients experience partial or full spontaneous recovery over weeks to months. However, up to 20% remain unable to walk at six months, and 60–80% of patients report residual deficits — persistent fatigue, distal weakness, impaired sensation, neuropathic pain or reduced exercise tolerance — that standard rehabilitation does not fully resolve.
Our programme targets these residual deficits. For patients whose recovery has plateaued after the acute phase, cellular therapy provides a biological mechanism to support remyelination, repair axonal damage and accelerate functional recovery beyond what the body achieves on its own.
AIDP (Acute Inflammatory Demyelinating Polyneuropathy)
The most common form in Europe and North America, representing approximately 60–80% of GBS cases. The immune attack targets the myelin sheath surrounding peripheral nerves. Recovery potential is generally favourable as the underlying axons remain largely intact. Demyelination is the primary therapeutic target.
AMAN (Acute Motor Axonal Neuropathy)
Predominantly affects motor axons without significant demyelination. More common in East Asia and Central/South America. Associated with Campylobacter jejuni infection and anti-ganglioside antibodies (anti-GM1, anti-GD1a). Recovery can be rapid in mild cases but prolonged when axonal degeneration is extensive.
AMSAN (Acute Motor-Sensory Axonal Neuropathy)
Affects both motor and sensory axons. Typically the most severe variant with slower, often incomplete recovery. Patients frequently retain significant residual sensorimotor deficits. Represents approximately 5–10% of GBS cases. Axonal regeneration is the primary therapeutic challenge.
Miller Fisher Syndrome
Characterised by the clinical triad of ophthalmoplegia (eye movement paralysis), ataxia and areflexia. Accounts for approximately 5% of GBS cases. Associated with anti-GQ1b antibodies. Generally carries a favourable prognosis, though some patients develop residual balance and coordination deficits.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates diagnosis, GBS variant, time since onset, current neurological status and recovery trajectory.
Clinical Outcomes
The following data are derived from structured observational analysis of GBS patients treated at BioCells Medical between 2016 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
36
GBS patients treated since 2013
80%
measurable functional stabilisation on MRC Sum Score at 3–6 months
+6.4 pts
average MRC Sum Score score change at 6 months — vs. expected +1.5 pts natural progression
75%
sustained functional stability with average 1.5 years of follow-up
80%
showed improvement in one or more measured domains
75%
retained independence in basic activities of daily living (ADL) at 12 months
Motor & strength (distal limb strength, grip function, independent ambulation)
77%
Sensory & pain (neuropathic pain, sensory recovery in hands and feet)
62%
Autonomic (exercise tolerance, post-exertional fatigue, walking aid dependency)
74%
Quality of life (daily independence, return to work/activity, sleep)
70%
1–4 weeks
Initial functional response
2–4 months
Clinically meaningful change
1–2 years onward
Long-term stability — continuous monitoring
Important: Outcomes depend on GBS variant, severity of axonal involvement, time since onset, baseline disability level and individual biological response. Patients with predominantly demyelinating forms (AIDP) generally show faster and more complete response.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationThe BioCells Program
Our GBS programme combines five biological components into a single personalised protocol. Each protocol is constructed following a detailed medical evaluation — accounting for the specific GBS variant, degree of axonal versus demyelinating damage, time since onset and residual functional deficits.
Minimally invasive administration
Treatment is delivered by intravenous infusion or targeted local injection using specialised medical systems — not surgical instruments.
No general anaesthesia
Relevant for GBS patients who may have residual autonomic instability or respiratory vulnerability.
No risk of immune rejection
MSCs are immunoprivileged: they express low levels of HLA-I, lack HLA-II and carry a minimal risk of rejection whether the protocol is autologous or allogeneic. Allogeneic MSC protocols do not require immunosuppression.
Targets the biological barriers to nerve recovery
Rather than relying on passive recovery alone, our protocol addresses residual inflammation, Schwann cell dysfunction and axonal regeneration failure — the biological reasons recovery stalls.
Complements standard rehabilitation
Our programme works alongside physiotherapy, occupational therapy and any existing medication. Patients do not need to discontinue current treatment before commencing our protocol.
Patients from around the world
We work with patients from around the world. Airport transfers, accommodation, visa support and multilingual coordination are included in every treatment programme.
What It Is
T-regs are specialised immune cells that naturally suppress destructive autoimmune processes. In GBS, the immune system attacks peripheral nerve components through molecular mimicry — T-regs restore immune tolerance and prevent continued immune-mediated nerve damage.
How It Is Done
Delivered autologously (from the patient's own blood) or allogeneically (from a certified donor), based on the patient's immune status and clinical assessment. Preparation and quality testing performed in our Warsaw laboratory.
Biological Mechanisms
How This Helps in Guillain-Barré Syndrome
GBS is driven by molecular mimicry — the immune system generates antibodies against infectious agents that cross-react with gangliosides on peripheral nerves. T-regs directly address this mechanism by restoring immune tolerance, suppressing the complement cascade that damages nerve membranes, and reducing the risk of ongoing subclinical immune activity that delays full recovery.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific GBS variant, time since onset, degree of axonal versus demyelinating damage, current functional status and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, GBS variant, current disability level, nerve conduction data and recovery trajectory. This consultation is free and carries no obligation.
A detailed review of all medical documentation — including nerve conduction studies, MRC grading and GBS Disability Scale score. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted local administration — no surgery, no general anaesthesia. Airport transfers, accommodation and visa support are included in the programme for international patients.
Structured rehabilitation sessions with our specialist, adapted to your current motor function and sensory status. Focused on progressive strengthening, balance training and functional recovery. Available at our clinic or remotely coordinated with your local physiotherapy team.
Your dedicated coordinator monitors functional status, tracks nerve conduction improvements and adjusts recommendations based on your recovery data. A medical-grade wearable bracelet supports continuous health tracking regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by GBS patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's clinical status has changed — including signs of relapse or autonomic instability — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Patients currently in the acute progressive phase of GBS requiring ICU management
Post-Treatment
Dedicated rehabilitation specialist
monitors motor recovery, sensory status and fatigue levels
Personalised rehabilitation programme
progressive strengthening, balance and endurance training adapted to current recovery phase
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in status
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Peripheral nerve regeneration is a gradual biological process. The period following treatment is as medically important as the treatment itself — consistent rehabilitation, monitoring and clinical follow-up are essential for sustained recovery.
Patient Stories
“Eight months after GBS I still needed two crutches and could not button a shirt. We completed the treatment programme. Gradually my grip returned. I started cooking again. Now I use one stick outdoors and nothing indoors. The fatigue went from crushing to manageable.”
Patient
GBS (AIDP) · United Kingdom
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationPatient Cases
Documented treatment outcomes recorded by the BioCells Medical team after personalised regenerative medicine protocols.
Get Started
If you or someone you care about has residual deficits following Guillain-Barré Syndrome, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, GBS variant, current functional status and recovery trajectory.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
